GEN Exclusives

More »

GEN News Highlights

More »
May 21, 2007

Morphotek Signs Development and Clinical Supply Deal with CMC Biopharmaceuticals

  • Morphotek okayed an agreement with CMC Biopharmaceuticals for GMP manufacturing and regulatory documentation support of MORAb-028, a therapeutic antibody targeting advanced melanoma and other cancers.

    MORAb-028 is a human IgM mAb that specifically recognizes a cell surface antigen over-expressed on a significant fraction of metastatic melanoma, brain cancers, and non-small-cell-lung carcinoma, according to Morphotek.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?